Cited by 6,683PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, Hannah, McCabe, Nuala, Lord, Christopher J., Tutt, Andrew N. J., Johnson, Damian A., Richardson, Tobias B., Santarosa, Manuela, Dillon, Krystyna J., Hickson, Ian, Knights, Charlotte, Martin, Niall M. B., Jackson, Stephen P., Smith, Graeme C. M., Ashworth, Alan·2005·Nature

DOI 10.1038/nature03445

Open this paper in CoChat — free account

Abstract

BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.

Integrity signals

Registry

Crossref · 10.1038/nature03445

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Self-citation
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks
Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00174-5 · Cited by 1,007
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T. H., Murcia, J. M., & de MURCIA, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 744
Breast and Ovarian Cancer
Wooster, R., & Weber, B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 619
The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin
Bhattacharyya, A., Ear, U., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 584
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes
Furuta, T., Takemura, H., Liao, Z.-Y., Aune, G. J., Redon, C., Sedelnikova, O. A., Pilch, D. R., Rogakou, E. P., Celeste, A., Chen, H. T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300198200 · Cited by 449

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 601–700 of 1,042

Pathology of hereditary breast cancer
van der Groep, P., van der Wall, E., & van Diest, P. J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0010-3 · Cited by 190
BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
Veeck, J., Ropero, S., Setién, F., González‐Suárez, E., Osório, A., Benitez, J. J., Herman, J. G., & Esteller, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1010 · Cited by 173
Cisplatin Resistance Associated with PARP Hyperactivation
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy
Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e31 · Cited by 181
DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints
You, Z., & Bailis, J. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.04.002 · Cited by 189
Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4
Kim, Y., Spitz, G. S., Veturi, U., Lach, F. P., Auerbach, A. D., & Smogorzewska, A. (2012) · Blood · doi:10.1182/blood-2012-07-441212 · Cited by 180
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Hastak, K., Alli, E., & Ford, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4521 · Cited by 177
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Tinoco, G., Warsch, S., Glück, S., Avancha, K. K. V. R., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 179
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors
Lim, K. S., Li, H., Roberts, E. A., Gaudiano, E. F., Clairmont, C. S., Sambel, L. A., Ponnienselvan, K., Liu, J., Yang, C., Kozono, D., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.045 · Cited by 174
REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps
Taglialatela, A., Leuzzi, G., Sannino, V., Cuella-Martin, R., Huang, J., Wu-Baer, F., Baer, R. J., Costanzo, V., & Ciccia, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.016 · Cited by 183
Fanconi anemia pathway–deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated
Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., la Vega, M. A. D., Moreau, L. A., Shimamura, A., & D’Andrea, A. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31245 · Cited by 178
BRCA 1, a ‘complex’ protein involved in the maintenance of genomic stability
Savage, K. I., & Harkin, D. P. (2014) · FEBS Journal · doi:10.1111/febs.13150 · Cited by 183
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Toledo, L. I., Murga, M., & Fernández-Capetillo, Ó. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.002 · Cited by 180
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 183
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
Sun, K., Mikule, K. W., Wang, Z., Poon, G. K., Vaidyanathan, A., Smith, G. C., Zhang, Z.-Y., Hanke, J. H., Ramaswamy, S., & Wang, J. (2018) · Oncotarget · doi:10.18632/oncotarget.26354 · Cited by 179
Self-citation
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Liu, J. F., Tolaney, S. M., Birrer, M. J., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E. P., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.020 · Cited by 177
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
Liu, X., Shi, Y., Maag, D., Palma, J. P., Patterson, M. J. S., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Oser, M. G., Fonseca, R., Chakraborty, A. A., Brough, R., Spektor, A., Jennings, R. B., Flaifel, A., Novak, J. S. S., Gulati, A., Buss, E. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0389 · Cited by 176
Self-citation
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 183
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wållberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 178
Self-citation
G-Quadruplex DNA as a Molecular Target for Induced Synthetic Lethality in Cancer Cells
McLuckie, K. I. E., Antonio, M. D., Zecchini, H. I., Xian, J., Caldas, C., Krippendorff, B., Tannahill, D., Lowe, C., & Balasubramanian, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja404868t · Cited by 177
Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells
Venere, M., Hamerlik, P., Wu, Q., Rasmussen, R. D., Song, L. A., Vasanji, A., Tenley, N., Flavahan, W. A., Hjelmeland, A. B., Bártek, J., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.136 · Cited by 181
Biomarker-Driven Early Clinical Trials in Oncology
Tan, D. S. W., THOMAS, G. V., Garrett, M. D., Banerji, U., Bono, J. S. D., Kaye, S. B., & Workman, P. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bd0445 · Cited by 173
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Arun, B., Bayraktar, S., Liu, D. D., Gutierrez‐Barrera, A. M., Atchley, D. P., Pusztai, L., Litton, J. K., Valero, V., Meric‐Bernstam, F., Hortobágyi, G. N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2682 · Cited by 174
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Genomic landscape of DNA repair genes in cancer
Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Santa-Maria, C. A., Platanias, L. C., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8196 · Cited by 174
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
Carrassa, L., & Damia, G. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.013 · Cited by 178
XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase
Fuss, J. O., & Tainer, J. A. (2011) · DNA Repair · doi:10.1016/j.dnarep.2011.04.028 · Cited by 170
miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
Sun, C., Li, N., Yang, Z., Zhou, B., He, Y., Weng, D., Fang, Y., Wu, P., Chen, P., Yang, X., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt302 · Cited by 173
The role of BRCA1 and BRCA2 in prostate cancer
Castro, E., & Eeles, R. A. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.150 · Cited by 175
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination–Mediated DNA Repair
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 181
Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Mylavarapu, S., Das, A., & Roy, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00016 · Cited by 175
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy
Schrempf, A., Slyšková, J., & Loizou, J. I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.007 · Cited by 172
Rational Design of Human DNA Ligase Inhibitors that Target Cellular DNA Replication and Repair
Chen, X., Zhong, S., Zhu, X., Dziegielewska, B., Ellenberger, T., Wilson, G. M., MacKerell, A. D., & Tomkinson, A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6636 · Cited by 173
XRCC1 protein; Form and function
Caldecott, K. W. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102664 · Cited by 176
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Riches, L. C., Trinidad, A. G., Hughes, G., Jones, G. N., Hughes, A. M., Thomason, A. G., Gavine, P. R., Cui, A., Ling, S., Stott, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1394 · Cited by 168
Self-citation
Cancer research: past, present and future
Cao, Y., DePinho, R. A., Ernst, M., & Vousden, K. H. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3138 · Cited by 170
Toward specific functions of poly(ADP-ribose) polymerase-2
Yélamos, J., Schreiber, V., & Dantzer, F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.003 · Cited by 177
Alternative end-joining pathway(s): Bricolage at DNA breaks
Frit, P., Barboule, N., Yuan, Y., Gómez, D., & Calsou, P. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.02.007 · Cited by 187
The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction
Langelier, M.-F., Ruhl, D. D., Planck, J. L., Kraus, W. L., & Pascal, J. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.105668 · Cited by 175
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Esposito, M. T., Zhao, L., Fung, T. K., Rane, J. K., Wilson, A., Martin, N., Gil, J., Leung, A. Y. H., Ashworth, A., & So, C. W. E. (2015) · Nature Medicine · doi:10.1038/nm.3993 · Cited by 174
Self-citation
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Turk, A. A., & Wisinski, K. B. (2018) · Cancer · doi:10.1002/cncr.31307 · Cited by 175
PARP inhibition impedes the maturation of nascent DNA strands during DNA replication
Vaitsiankova, A., Burdová, K., Sobol, M. A., Gautam, A., Benada, O., Hanzlíková, H., & Caldecott, K. W. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00747-1 · Cited by 172
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 168
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo‐Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 169
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Lev, S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191055 · Cited by 172
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Kim, D.-S., Camacho, C. V., & Kraus, W. L. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00557-3 · Cited by 172
ABC ATPase signature helices in Rad50 link nucleotide state to Mre11 interface for DNA repair
Williams, G. J., Williams, R. S., Williams, J. S., Moncalián, G., Arvai, A. S., Limbo, O., Guenther, G., SilDas, S., Hammel, M., Russell, P. R., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2038 · Cited by 171
Germline Brca2 Heterozygosity Promotes Kras -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
Skoulidis, F., Cassidy, L. D., Pisupati, V., Jonasson, J. G., Bjarnason, H., Eyfjord, J. E., Karreth, F. A., Lim, M., Barber, L. M., Clatworthy, S. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.015 · Cited by 169
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
Xu, Y., & Her, C. (2015) · Biomolecules · doi:10.3390/biom5031652 · Cited by 169
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
Tan, D. S. P., Lambros, M. B. K., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchiò, C., Geyer, F. C., Savage, K., Parry, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2403 · Cited by 165
Self-citation
Hereditary breast cancer; Genetic penetrance and current status with BRCA
Mahdavi, M., Nassiri, M., Kooshyar, M. M., Azghandi, M. V., Avan, A., Sandry, R., Pillai, S., Lam, A. K.-Y., & Gopalan, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27464 · Cited by 181
Targeting the DNA repair defect of BRCA tumours
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.006 · Cited by 164
Self-citation
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Oplustilova, L., Wolanin, K., Mistrík, M., Kořínková, G., Šimková, D., Bouchal, J., Lenobel, R., Bártková, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 167
PolyADP‐ribosylation and cancer
Miwa, M., & Masutani, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00567.x · Cited by 165
PARP Inhibitor Treatment in Ovarian and Breast Cancer
Weil, M. K., & Chen, A. P. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2010.12.002 · Cited by 163
Targeting the DNA Damage Response in Cancer
Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 164
SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance
Schorge, J. O., Modesitt, S. C., Coleman, R. L., Cohn, D. E., Kauff, N. D., Duska, L., & Herzog, T. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.06.003 · Cited by 163
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W. M., O’Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 168
Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization
Jönsson, G. B., Naylor, T. L., Vallon‐Christersson, J., Staaf, J., Huang, J., Ward, M. R., Greshock, J. D., Luts, L., Olsson, H. L., Rahman, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0570 · Cited by 163
Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia
Bindra, R. R., & Glazer, P. M. (2006) · Oncogene · doi:10.1038/sj.onc.1210001 · Cited by 167
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Toft, D. J., & Cryns, V. L. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0164 · Cited by 173
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Gossage, L., & Madhusudan, S. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.001 · Cited by 162
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Drew, Y., Ledermann, J. A., Hall, G. D., Rea, D. W., Glasspool, R. M., Highley, M., Jayson, G. C., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 163
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Liu, Y., Burness, M. L., Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R. A., Brooks, M. D., Li, S., Fox, A. L., Luther, T. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1348 · Cited by 168
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination
Zhao, W., Wiese, C., Kwon, Y., Hromas, R., & Sung, P. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111058 · Cited by 169
A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
Shu, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Clinical Epidemiology · doi:10.2147/clep.s365513 · Cited by 163
Management of breast cancer with targeted agents: importance of heterogenicity
Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159
B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity
Aguiar, R. C. T., Takeyama, K., He, C., Kreinbrink, K., & Shipp, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505408200 · Cited by 171
Therapeutic Targeting of the DNA Mismatch Repair Pathway
Martin, S. A., Lord, C. J., & Ashworth, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0821 · Cited by 164
Self-citation
DNA methylation biomarkers in cancer: progress towards clinical implementation
Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.45 · Cited by 161
Validating cancer drug targets
Benson, J. D., Chen, Y.-N. P., Cornell-Kennon, S., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W. R., & Lengauer, C. (2006) · Nature · doi:10.1038/nature04873 · Cited by 162
BRCA mutations in the management of breast cancer: the state of the art
Narod, S. A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.166 · Cited by 160
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 166
Epithelial ovarian cancer: An overview
Desai, A. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i1.1 · Cited by 161
Leveraging big data to transform target selection and drug discovery
Chen, B., & Butte, A. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.318 · Cited by 165
Drugging the Cancers Addicted to DNA Repair
Nickoloff, J. A., Jones, D. V., Lee, S., Williamson, E. A., & Hromas, R. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 163
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, S., Porta, N., Arce‐Gallego, S., Seed, G., Llop‐Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C. M., Baker, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0007 · Cited by 158
Self-citation
PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends
Chappidi, N., Quail, T., Doll, S., Vogel, L. T., Aleksandrov, R., Felekyan, S., Kühnemuth, R., Stoynov, S., Seidel, C. A. M., Jan Brugués, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.015 · Cited by 164
Mechanisms of BRCA1 Tumor Suppression
Silver, D. P., & Livingston, D. M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0221 · Cited by 159
LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy
Saha, T. (2012) · Autophagy · doi:10.4161/auto.21654 · Cited by 163
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Wang, Z. C., Birkbak, N. J., Culhane, A. C., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K. E., Piao, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0857 · Cited by 159
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Hassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gülsüner, S., Gadiraju, M., Panou, V., Gao, S., Mian, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821510116 · Cited by 155
BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer
James, C. R., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-142 · Cited by 163
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4508 · Cited by 158
Poly(ADP-ribose) makes a date with death
Heeres, J. T., & Hergenrother, P. J. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.08.038 · Cited by 167
Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer‐predisposing gene
Bártková, J., Tommiska, J., Oplustilova, L., Aaltonen, K., Tamminen, A., Heikkinen, T., Mistrík, M., Aittomäki, K., BLOMQVIST, C. P., Heikkilä, P., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.09.007 · Cited by 164
Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors
Neri, P. E., Ren, L., Gratton, K., Stebner, E., Johnson, J., Klimowicz, A. C., Duggan, P. R., Tassone, P., Mansoor, A., Stewart, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363911 · Cited by 159
Structural Implications for Selective Targeting of PARPs
Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00301 · Cited by 168
TRIP13 regulates DNA repair pathway choice through REV7 conformational change
Clairmont, C. S., Sarangi, P., Ponnienselvan, K., Galli, L. D., Csete, I., Moreau, L. A., Adelmant, G., Chowdhury, D., Marto, J. A., & D’Andrea, A. D. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0442-y · Cited by 161
Repair of Oxidative DNA Damage and Cancer: Recent Progress in DNA Base Excision Repair
Scott, T. L., Rangaswamy, S., Wicker, C. A., & Izumi, T. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5529 · Cited by 162
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K. M., Farrelly, A. M., Gallagher, D., Busschots, S., Renaud, M., Thery, J., Williams, D., Potter, J., Tran, T., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2012.12.007 · Cited by 161
Moonlighting at replication forks – a new life for homologous recombination proteins BRCA 1, BRCA 2 and RAD 51
Kolinjivadi, A. M., Sannino, V., Antoni, A. D., Técher, H., Baldi, G., & Costanzo, V. (2017) · FEBS Letters · doi:10.1002/1873-3468.12556 · Cited by 155
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Mazzu, Y. Z., Armenia, J., Chakraborty, G., Yoshikawa, Y., Coggins, S. A., Nandakumar, S., Gerke, T. A., Pomerantz, M. M., Qiu, X., Zhao, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4046 · Cited by 156
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
Hanna, C. R., Kurian, K. M., Williams, K., Watts, C., Jackson, A., Carruthers, R., Strathdee, K. E., Cruickshank, G. S., Dunn, L., Erridge, S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa104 · Cited by 163
The systemic treatment of recurrent ovarian cancer revisited
Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martı́n, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 157

Authors: Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A.
Affiliations: Cancer Research UK (GB)
Institute of Cancer Research (GB)
Guy's Hospital (GB)
University of Cambridge (GB)
Corresponding author: Smith, Graeme C. M.
Ashworth, Alan
ORCID: Lord, Christopher J.
Tutt, Andrew N. J.
Santarosa, Manuela
Hickson, Ian
Martin, Niall M. B.
Jackson, Stephen P.
Smith, Graeme C. M.
Ashworth, Alan
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04
Volume: 434
Issue: 7035
Pages: 917-921
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03445
OpenAlex: W1973268287
Cited by: 6,683
References: 24
Citations by year: 2026: 271 · 2025: 346 · 2024: 356 · 2023: 454 · 2022: 443 · 2021: 502 · 2020: 460 · 2019: 382 · 2018: 381 · 2017: 353 · 2016: 358 · 2015: 315 · 2014: 312 · 2013: 292 · 2012: 262
FWCI: 68.30
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: Cancer Research UK
National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: BRCA1, BRCA2, PARP inhibitors, homologous recombination, base excision repair, synthetic lethality, breast cancer, DNA double-strand break repair, chromosomal instability, cell cycle arrest, apoptosis, targeted cancer therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Cell Survival, DNA Damage, DNA Repair, Mice, Nude, Models, Biological, Mutation, Neoplasms, Poly(ADP-ribose) Polymerases, Substrate Specificity, Apoptosis, Genes, BRCA1, Xenograft Model Antitumor Assays, Genes, BRCA2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks